

Human Cystatin C

[İnsan Sistatin C'si]

¹Pika Mesko Brguljan ,

²Nina Cimerman

¹University Clinic for Respiratory Diseases and Allergy Golnik, Golnik 36, 4204 Golnik, Slovenia.

²Research and Development Division, Krka, d.d., Šmarješka cesta 6, 8000 Novo mesto, Slovenia.

Yazışma Adresi

[Correspondence Address]

Dr. Pika Mesko Brguljan

University Clinic for Respiratory Diseases and Allergy Golnik

Clinical Chemistry Department

Golnik 36 4204 Golnik, Slovenia

Tel. +386 4 25 69 421

Fax: +386 4 25 69 117

Mobile: +386 41 289 448

E-mail: pika.mesko@klinika-golnik.si

ABSTRACT

Cystatin C, a low molecular weight inhibitor of cysteine proteases, is involved in various biological and pathological processes. Recently, serum cystatin C has been proposed to be a valuable alternative marker of glomerular filtration rate, particularly in situations in which creatinine fails to provide an accurate estimate of renal impairment. However, the use of cystatin C is interfered by nonrenal factors such as glucocorticoid therapy, malignancy or thyroid disorders, which influence serum cystatin C concentrations. The clinical utility of cystatin C as a renal marker is under evaluation. The standardisation of methods for cystatin C is necessary.

Key Words: Cystatin C, renal function, diagnostic parameter

ÖZET

Sistein proteazların düşük molekül ağırlıklı bir inhibitörü olan Sistatin C, çeşitli biyolojik ve patolojik olaylarda rol alır. Son yıllarda, serum sistatin C'sinin, özellikle kreatinin böbrek hasarını doğru olarak değerlendirmede yararlı olmadığı zaman, glomerüler filtrasyon hızı ölçümü için değerli bir belirteç alternatifi olduğu öne sürülmüştür. Ancak, sistatin C'nin kullanımı serum sistatin C düzeyini etkileyen glukokortikoid tedavisi, kanser veya tiroid bozuklukları gibi böbrek dışı nedenlerden etkilenir. Sistatin C'nin renal belirteç olarak klinikte kullanımı halen inceleme aşamasındadır. Sistatin C metodlarının standardizasyonu gerekmektedir.

Anahtar Kelimeler: Sistatin C, böbrek fonksiyonu, tanısal parametre

1. HUMAN CYSTATIN C – HISTORY AND CHARACTERISTICS

Cystatin C is a non-glycosylated, basic, low molecular weight protein; it was initially described as a microprotein constituent of normal cerebrospinal fluid, and of urine from patients with renal failure [1,2]. The early literature referred to it by several different names such as γ -trace, post- γ -globulin, and gamma-CSF before it was sequenced [3]. The amino acid sequence of cystatin C isolated from human urine was the first determined sequence of the cystatin superfamily [3]. The same protein was only two years later identified as an inhibitor of cysteine proteases [4,5].

Cystatin C is the part of a superfamily of cysteine protease inhibitors [6-8]. The cystatin superfamily is comprised of a large group of ancestrally related proteins active against papain-type proteases that are divided to three major families: the type 1 cystatins, which include stefins A and B, and are mainly intracellular; the type 2 cystatins, which include cystatins C, D, E/M, F, G, S, SN and SA, and are extracellular; and the type 3 cystatins, which include the kininogens, and are intravascular proteins [9]. Cystatin C is the most potent inhibitor of cysteine proteases such as lysosomal cathepsins B, H, L and S, with apparent inhibition constants even below nanomolar range [4,8,10-11]. Mature cystatin C is composed of 120 amino acid residues and it is synthesized as a preprotein with a 26-residue signal peptide [12]. The presence of a hydrophobic leader sequence in pre-cystatin C strongly indicates that the protein is normally secreted. Cystatin C gene is ubiquitously expressed in all tissues and cell types, and it is present in relatively high concentration in a number of body fluids, although mRNA levels vary several-fold between and among tissues [13-15]. There are considerable differences in the extracellular levels of cystatin C; it is present at micromolar levels in cerebrospinal fluid and semen, while in serum, saliva, and tears its concentration is much lower [7,13]. In some body compartments, as for instance in cerebrospinal fluid, cystatin C represents more than 90 % of the total molar concentration of cysteine protease inhibitors, while in blood plasma, it only represents a few percent of the total cysteine protease inhibitory capacity. Cystatin C can inactivate their target enzymes either extracellularly or intracellularly, following reuptake [16]. During intracellular trafficking cystatin C forms a dimer. The dimerisation of cystatin C resulted in a complete loss of its biological activity [17]. Although cystatin C gene has typical features of a constitutively expressed “housekeeping” gene, and is not an acute-phase protein [18], cystatin C levels are regulated in a manner that suggests a relationship to injury and immune responses [19-24]. Additional function attributed to cystatin C is an efficient inhibition of legumain, also called asparaginyl endopeptidase (APE), which has, like cathepsin S, been proposed to be involved in the class II MHC presentation of antigens [25-29]. A non-

inhibitory mode of interaction between cysteine proteases and cystatin C, where cathepsin L cleaves cystatin C at Gly11-Gly12 bond upon complexation, was determined [30]. Since both proteins are extracellular it was suggested that such cleavage could be of physiological importance by controlling the extent of inhibition of cysteine proteases, especially cathepsin B, at the site of inflammation [31]. Independent of its effects on cysteine protease activity, cystatin C also regulates normal and transformed cell proliferation [32], inhibits melanoma cell motility [33], as well as antagonizes transforming growth factor β signalling in normal and cancer cells [34]. It was also suggested that cystatin C has a regulatory role in inflammatory processes by down-regulation of phagocytosis-associated respiratory burst reaction displayed by polymorphonuclear neutrophils and by down-regulation of their chemotactic response [35]. Another property unrelated to its potential of cysteine protease inhibitor is upregulation of nitric oxide release [36]. These findings define novel cathepsin-independent functions for cystatin C.

Another feature, which is common for type 2 cystatins, is N-terminal processing [37-39]. A different N-terminal truncation of cystatin C was observed in urine from patients with nephrological disorders [40-42], purulent sputum [43], amyloid deposits in brain arteries [44,45], and in cerebrospinal fluid of patients with hereditary cystatin C amyloid angiopathy [46]. The inhibitory effect of cystatin C on extracellular cysteine proteases may be reduced by the existence of truncated forms of the inhibitor as described by *in vitro* experiments with variety of proteases [10,30,31,40,47]. It is believed that N-terminal truncations are the result of proteolytic cleavage of the full-length cystatin C, since the N-terminal part is exposed in the outer side of the molecule and has no ordered structure in solution as revealed from X-ray crystallography and nuclear magnetic resonance spectroscopy [48-53]. Indeed, such inactivation of cystatin C has already been observed *in vitro* following the action of papain [54], neutrophil elastase [43], cathepsin L [30], and gingipain [55]. Leung-Tack et al. [35] suggested the role of cystatin C, and N-terminal processing, in the modulation of neutrophil behavior. Cystatin C has been proposed to have a role as an intracellular modulator of MHC class-II-mediated antigen presentation in peripheral dendritic cells by controlling cathepsin-S-mediated degradation of the invariant chain [56]. However, later results revealed that cystatin C expression can differ markedly between closely related cell types [57]. This expression pattern is very striking, because cystatin C has generally been considered a ubiquitously expressed protein and its gene contains no obvious regulatory sequences that might explain this feature. Furthermore, it was also reported that cystatin C is neither necessary nor sufficient to control MHC II expression and antigen presentation in dendritic cells [57].

Alterations in balance of cysteine proteases and cys-

tatins have been associated with several disease conditions. Cystatin C is thought to play a role in periodontal disease [58-60], inflammation [43,61,62], cancer [63,64], multiple sclerosis [65], renal failure [66], asthma [67-69], HIV infection [70], bone remodeling [71], etc. Due to the widespread extracellular distribution of cystatin C and the antiviral function demonstrated for cystatins in experiments with polio, herpes simplex, and corona virus-infected cell cultures, one of suggested roles of cystatin C is a defence against microbial and viral infections [72-75]. Despite the fact that the biological function of cystatin C is not yet fully determined, cystatin C concentrations in extracellular fluids have been shown to be of clinical importance.

2. CYSTATIN C AND RENAL FUNCTION

Assessment and follow-up of renal dysfunction is important in the early detection and management of chronic kidney disease. The glomerular filtration rate (GFR) is considered the most accurate measurement of kidney disease and is reduced before the onset of clinical symptoms. GFR is measured or predicted according to different methods. The most precise and accurate method for evaluation of kidney function is the measurement of GFR using particular exogenous substance. However, the use of these filtration markers makes measurement of GFR costly and incompatible with routine monitoring [76]. Use of endogenous substance creatinine as markers of GFR is the most commonly used biochemical parameter, which provides an approximate index of the level of GFR [76-78]. Intra-individual variation of creatinine is low, but its concentrations differ considerably between people because factors such as muscle mass, protein intake, age, sex, race and extrarenal metabolism can influence creatinine production, and lead to an inaccurate estimation of GFR. Creatinine clearance gives a better estimate of GFR than does serum creatinine, but requires the inconvenience of urine collection. Serum creatinine is of limited value in early detection of renal impairment, while creatinine clearance overestimates true GFR because creatinine is not only filtered by the renal glomeruli but is also secreted by the tubules [79]. According to National Kidney Foundation-K/DOQI clinical guidelines for chronic kidney disease, serum markers should not be used alone to assess GFR. Clinical laboratory should report an estimate GFR using prediction equations [80].

Knowledge of GFR is of crucial importance in the management of patients to allow correct dosage of drugs cleared by the kidneys, to detect early impairment of renal function, to prevent further deterioration, to manage renal transplant patients and for use of potentially nephrotoxic radiographic contrast media. In specific patient populations where creatinine measurements are crude and can often be misleading, there is a need for more reliable measurement of GFR [81].

The fact that cystatin C exhibits a stable production rate in all nucleated cells, that it is freely filtered in renal

glomeruli and almost completely reabsorbed and catabolized in proximal tubules, suggested that its plasma or serum concentrations might be a potentially good marker for GFR. Indeed, many studies during the last few years observed a correlation between serum cystatin C and GFR [82-85]. Serum cystatin C has been shown to be at least as good a measure of GFR as serum creatinine and several advantages to the use of cystatin C were cited [86,87]. According to the temporal analysis the time of serum sampling in healthy subjects did not compromise the results of quantitative measurements of cystatin C over the course of a day [88], supporting its usefulness for clinical evaluation as diagnostic tool. It also appears that the disease and the type of therapy did not influence the circadian characteristics of serum cystatin C, which was demonstrated in a clinical study that included asthma patients receiving methylprednisolon therapy [67]. Several studies have revealed the normal population range of cystatin C, which after the age of one year is remarkably constant [84, 89-91]. Cystatin C is higher before age of three months and after the age of seventy [92,93].

Multiple studies have validated the use of cystatin C as a renal marker to perform at least as well as serum creatinine in the population at large and that it is likely to be superior in specific patient populations [94, 95]. Cystatin C was found to be a more sensitive marker than serum creatinine for small changes in GFR [83,94], and for earlier indication of mild renal failure [96-99]. Several cystatin C-based prediction equations for calculation of GFR have been published in the last years for adults and children. These formulas were evaluated with different cystatin C assays and may reveal inaccurate GFR estimates if inappropriate formula is used for a cystatin C result [76,100], therefore, the availability of the internationally standardised methods for cystatin C is important [101,102].

2.1. Cystatin C in Pediatric Population

In pediatric populations cystatin C may have advantage over routinely used endogenous markers of GFR because of the low muscle mass in children, which leads to very low serum creatinine values and thus to increased assay imprecision. In pediatric patients the urine collection is impossible, as well as in neonates where cystatin C, in contrast to creatinine, does not cross the fetoplacental barrier [93,103-107]. Another advantage is that cystatin C concentration appears to be rather constant in children after the age of one and similar to that of adults [92,93,102,109]. In addition, it has been shown that cystatin C is the only marker of GFR that is reliable in patients with spina bifida or spinal cord injury [110,111]. Serum cystatin C was confirmed as easy and useful marker, better than creatinine, to detect acute kidney injury in critically ill children [112].

2.2. Cystatin C in Elderly Population

The limitations of serum creatinine, namely low muscle mass and age, for this population are similar to pediatric population. Serum cystatin C was shown to be a superior marker for the early detection of renal impairment in the elderly compared to creatinine [96,113-115].

2.3. Cystatin C in Pregnancy

Increased cystatin C concentrations were found in healthy women at term pregnancy when compared to healthy controls [116] and significantly lower cystatin C concentrations were detected in serum of patients with recurrent miscarriage [117]. Cystatin C was shown to be a more sensitive indicator of early renal function decline in women with pre-eclampsia [118,119]. At the same time serum cystatin C was suggested as a marker of endotheliosis, where higher concentrations have been associated with the degree of endotheliosis in women with pre-eclampsia [120]. It therefore appears that monitoring of the degree of endotheliosis by determination of serum cystatin C might considerably reduce the need for renal biopsy in pre-eclampsia. More results are needed to establish cystatin C as a clinical marker of renal disease in pregnancy.

2.4. Cardiovascular Disease

Renal impairment is associated with bad prognosis. Even moderately reduced renal function represents increased risk of cardiovascular morbidity and mortality. Cystatin C was determined as a stronger predictor of mortality than creatinine in elderly persons with heart failure [121]. Recently, it was concluded on the bases of eight years long study including 4384 persons, 65 years of age or older, and without previous heart failure that serum cystatin C concentration is an independent risk factor of heart failure in older adults [122]. In addition serum cystatin C concentration appeared to be a better predictor of the risk of death and cardiovascular disease than serum creatinine concentration [122-123]. Thus, cystatin C was shown to be not just a useful alternative measure of renal function, but also an effective prognostic tool. The mechanism by which cystatin C concentration predicts risk of heart failure remains unclear. Koenig et al. [124] demonstrated that increased cystatin C concentrations are strongly associated with future secondary cardiovascular events, indicating cystatin C as a promising and clinically useful marker for risk determination in patients with coronary heart disease. It was also published that cystatin C detects reduce GFR more reliably and at earlier stage in patients undergoing cardiac catheterization allowing a better identification of patients with renal dysfunction and those at risk of contrast damage [125].

2.5. Renal Transplantation

Several studies gave varying results of the use of cystatin C as a marker for GFR in renal transplant patients [126-128]. For some authors, serum cystatin C was a better GFR marker than creatinine in renal transplant patients [127-131], for others, serum cystatin C was not a reliable marker because it was observed to be falsely increased in transplant patients compared with non-transplant patients with a similar GFR [132-133]. On the other hand, the largest study with 110 kidney recipients demonstrated that serum cystatin C accurately reflected creatinine clearance over the entire range of transplant function and was as efficacious as serum creatinine [134]. Complicating the value of cystatin C in renal transplant patients is our study in asthmatic patients demonstrating that corticosteroids can increase cystatin C whereas cyclosporine can decrease cystatin C values, both of which most transplant patients will receive [67].

2.5. Liver and Other Diseases

Cystatin C was proposed as superior marker from creatinine in patients with liver cirrhosis or after liver transplantation where determination of GFR by creatinine clearance fails because of their decreased muscle mass and increased tubular secretion of creatinine [135-141]. Cystatin C was demonstrated as better marker of GFR prediction than creatinine in patients with diabetes [142-146], and rheumatoid arthritis patients [147]. Cystatin C was reported to be an accurate marker of subtle changes in GFR of critically ill patients [112,148].

3. NONRENAL FACTORS ALTERING CYSTATIN C PRODUCTION

So far in most reports serum cystatin C concentrations were uninfluenced by age, gender or muscle mass [66,82-93]. However, just recently Knight et al. [86] concluded from a cross-sectional study of 8058 inhabitants in Netherlands that serum cystatin C appeared to be influenced by nonrenal factors such as age, gender, weight, height, current cigarette smoking, and C-reactive protein (CRP), which is in line with results obtained in another large population of 1033 patients with coronary heart disease [124]. The observed association between levels of cystatin C and that of CRP was first reported in an apparently healthy elderly population which could relate cystatin C concentrations to the inflammatory conditions [149].

Another non-renal factor which was found to alter serum cystatin C concentrations in different diseases is corticosteroid therapy [67,127,150-152]. Corticosteroid increase of cystatin C concentrations was probably due to a promoter-mediated increase in transcription of the cystatin C gene which was observed in glucocorticoid-induced HeLa cells [153].

Thyroid function is another condition which has to be considered when cystatin C is used as a marker of kidney function [154-158]. Even mild thyroid dysfunction is

associated with significant changes in cystatin C where hypothyroidism leads to lower cystatin C concentrations and hyperthyroidism leads to higher cystatin C concentrations.

Several investigators have demonstrated increased cystatin C concentrations in sera, pleural effusions, and ascetic fluids collected from cancer patients [63,64]. However, there are also contradictory reports claiming that malignancy had no effect on serum cystatin C concentrations [159-161]. Significant correlation between increased serum cystatin C and malignant progression in melanoma and colorectal cancer in the absence of any changed creatinine values have been revealed [162-164]. Additional prospective studies providing actual determination of GFR by clearance of creatinine or exogenous substances such as inulin will be necessary to assess the utility of cystatin C for early detection of reduced renal function in cancer and metastatic diseased patients.

4. CONCLUSION

It has been proposed that cystatin C has a general role in protection against proteolytic tissue injury by cysteine proteases released during normal processes, or as a result of an insult, and may serve as a marker for damaged regions. According to recent studies cystatin C determination could contribute to the diagnosis and treatment of various diseases and it could become a significant marker in clinical diagnosis. Several studies demonstrated that serum cystatin C is a valuable marker of GFR [76,81,86,87,94]. Furthermore, it was suggested that cystatin C will be used as a marker of GFR in certain patient populations where serum creatinine is inadequate in assessing renal function. However possible non-renal factors other than glucocorticoids [67,127,150-152] or thyroidism [154-158], which may influence serum cystatin C concentrations, must be investigated. The development of internationally standardised methods for cystatin C is very important [101,102].

References

[1] Clausen, J. 1961, Proteins in normal cerebrospinal fluid not found in serum. *Proc. Soc. Exp. Biol. Med.* 107, 170.

[2] Butler, E.A., and Flynn, F.V. 1961, The occurrence of post-gamma protein in urine: a new protein abnormality. *J. Clin. Pathol.* 14, 172.

[3] Grubb, A., and L_fberg, H. 1982, Human gamma-trace, a basic microprotein: amino acid sequence and presence in the adeno-hypophysis. *Proc. Natl. Acad. Sci. USA* 79, 3024.

[4] Brzin, J., Popovic, T., Turk, V., Borchart, U., and Machleidt, W. 1984, Human cystatin, a new protein inhibitor of cysteine proteases. *Biochem. Biophys. Res. Commun.* 118(1), 103.

[5] Schwabe, C., Anastasii, A., Crow, H., McDonald, J.K., and Barrett, A.J. 1984, Cystatin. Amino acid sequence and possible secondary structure. *Biochem. J.* 217, 813.

[6] Barrett, A.J., Rawlings, N.D., Davies, M.E., Machleidt, W., Salvesen, G., and Turk, V. 1986 Cysteine protease inhibitors of cystatin superfamily. In: *Protease Inhibitors*, A.J. Barrett, G. Salvesen (Ed.), Elsevier, Amsterdam, 515.

[7] Henskens, Y.M.C., Veerman, E.C.I., and Nieuw Amerongen, A.V. 1996, Cystatins in health and disease. *Biol. Chem. Hoppe-Seyler* 377, 71.

[8] Turk, B., Turk, V., and Turk, D. 1997, Structural and functional aspects of papain-like cysteine proteases and their protein inhibitors. *Biol. Chem.*, 1997, 378, 141.

[9] Abrahamson, M., Alvarez-Fernandez, M., and Nathanson, C.-M. 2003, Cystatins. *Biochem. Soc. Symp.* 70, 179.

[10] Cimerman, N., Trstenjak Prebada, M., Turk, B., Popovic, T., Dolenc, I., and Turk, V. 1999, Interaction of cystatin C variants with papain and human cathepsins B, H and L. *J. Enzym. Inhib.* 14, 167.

[11] Turk, V., Turk, B., Guncar, G., Turk, D., and Kos, J. 2002, Lysosomal cathepsins: structure, role in antigen processing and presentation, and cancer. *Advan. Enzyme regul.* 42, 285.

[12] Abrahamson, M., Grubb, A., Olafsson, I., and Lundwall, A. 1987, Molecular cloning and sequence analysis of cDNA coding for the precursor of the human cysteine protease inhibitor cystatin C. *FEBS Lett.* 216, 229.

[13] Abrahamson, M., Barrett, A.J., Salvesen, G., and Grubb, A. 1986, Isolation of six cysteine protease inhibitors from human urine. Their physicochemical and enzyme kinetic properties and concentrations in biological fluids. *J. Biol. Chem.* 261, 11282.

[14] Abrahamson, M., Olafsson, I., Palsdottir, A., Ulvsback, M., Lundwall, A., Jensson, O., and Grubb, A. 1990, Structure and expression of the human cystatin C gene. *Biochem. J.* 268, 287.

[15] Corticchiato, O., Cajot, J.F., Abrahamson, M., Chan, S.J., Keppler, D., and Sordat, B. 1992, Cystatin C and cathepsin B in human colon carcinoma: expression by cell lines and matrix degradation. *Int. J. Cancer* 52, 645.

[16] Merz, G.S., Benedikz, E., Schwenk, V., Johansen, T.E., Vogel, L.K., Rushbrook, J.I., and Wisniewski, H.M. 1997, Human cystatin C forms an inactive dimer during intracellular trafficking in transfected CHO cells. *J. Cell Physiol.* 173, 423.

[17] Eikel, I., and Abrahamson, M. 1996, Folding-related dimerization of human cystatin C. *J. Biol. Chem.* 271(3), 1314.

[18] Cole, T., Dickson, P.W., Esnard, F., Averill, S., Risbridger, G.P., Gauthier, F., and Schreiber, G. 1989, The cDNA structure and expression analysis of the genes for the cysteine protease inhibitor cystatin C and for beta 2-microglobulin in rat brain. *Eur. J. Biochem.* 186, 35.

[19] Warfel, A.H., Zucker-Franklin, D., Frangione, B., and Ghiso, J. 1987, Constitutive secretion of cystatin C (gamma-trace) by monocytes and macrophages and its downregulation after stimulation. *J. Exp. Med.* 166(6):1912.

[20] Hashimoto, S., Suzuki, T., Nagai, S., Yamashita, T., Toyoda, N., and Matsushima, K. 2000, Identification of genes specifically expressed in human activated and mature dendritic cells through serial analysis of gene expression. *Blood* 96, 2206.

[21] Suzuki, T., Hashimoto, S., Toyoda, N., Nagai, S., Yamazaki, N., Dong, H.Y., Sakai, J., Yamashita, T., Nukiwa, T., and Matsushima, K. 2000, Comprehensive gene expression profile of LPS-stimulated human monocytes by SAGE. *Blood* 96(7), 2584.

[22] Solem, M., Rawson, C., Lindburg, K., and Barnes, D. 1990, Transforming growth factor beta regulates cystatin C in serum-free mouse embryo (SFME) cells. *Biochem. Res. Commun.* 172, 945.

[23] Shi, G.P., Sukhova, G.K., Grubb, A., Ducharme, A., Rhode, L.H., Lee, R.T., Ridker, P.M., Libby, P., and Chapman, H.A. 1999, Cystatin C deficiency in human atherosclerosis and aortic aneurysms. *J. Clin. Invest.* 104 (9), 1191.

[24] Alfonso, S., Tovar, C., Romagnano, L., and Babiarz, B. 2002, Control and expression of cystatin C by mouse decidual cultures. *Mol. Reprod. Dev.* 61, 155.

- [25] Chapman, H.A., Reilly, J.J., Yee, R., and Grubb, A. 1990, Identification of cystatin C, a cysteine protease inhibitor, as a major secretory product of human alveolar macrophages in vitro. *Am. Rev. Respir. Dis.* 141, 698.
- [26] Chapman, H.A., Riese, R.J., and Shi, G.P. 1997, Emerging roles for cysteine proteases in human biology. *Annu. Rev. Physiol.* 59, 63.
- [27] Manoury, B., Hewitt, E., Morrice, N., Dando, P.M., Barrett, A.J., and Watts, C. 1998, An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation. *Nature* 396(6712), 695.
- [28] Chen, J.M., Rawlings, N.D., Stevens, R.A., and Barrett, A.J. 1998, Identification of the active site of legumain links it to caspases, clostripain and gingipains in a new clan of cysteine endopeptidases. *FEBS Lett.* 441, 301.
- [29] Alvarez-Fernandez, M., Barrett, A.J., Gerhartz, B., Dando, P.M., Ni, J., and Abrahamson, M. 1999, Inhibition of mammalian legumain by some cystatins is due to a novel second reactive site. *J. Biol. Chem.* 274, 1995.
- [30] Popovic, T., Cimerman, N., Dolenc, I., Ritonja, A., and Brzin, J. 1999, Cathepsin L is capable of truncating cystatin C of 11 N-terminal amino acids. *FEBS Lett.* 455, 92.
- [31] Abrahamson, M., Mason, R.W., Hansson, H., Buttle, D.J., Grubb, A., and Ohlsson, K. 1991, Human cystatin C. role of the N-terminal segment in the inhibition of human cysteine proteases and in its inactivation by leucocyte elastase. *Biochem. J.* 273, 621
- [32] Sun, Q. 1989, Growth stimulation of 3T3 fibroblasts by cystatin. *Exp. Cell. Res.* 180, 150.
- [33] Tavera, C., Leung-Tack J., Prevot, D., Gensac, M.C., Martinez, J., Fulcrand, P., and Colle, A. 1992, Cystatin C secretion by rat glomerular mesangial cells: autocrine loop for in vitro growth-promoting activity. *Biochem. Biophys. Res. Commun.* 182, 1082
- [34] Sokol, J.P., and Schiemann, W.P. 2004, Cystatin C antagonizes transforming growth factor beta signaling in normal and cancer cells. *Mol. Cancer Res.* 2, 183.
- [35] Leung-Tack, J., Tavera, C., Gensac, M.C., Martinez, J., and Colle, A. 1990, Neutrophil chemotactic activity is modulated by human cystatin C, an inhibitor of cysteine proteases. *Exp. Cell. Res.* 188, 16.
- [36] Verdout, L., Lalmanach, G., Vercauysse, V., Hartmann, S., Lucius, R., Hoebeke, J., Gauthier, F., and Vray, B. 1996, Cystatins up-regulate nitric oxide release from interferon-gamma-activated mouse peritoneal macrophages. *J. Biol. Chem.* 271 (45), 28077.
- [37] Esnard, F., Esnard, A., Faucher, D., Capony, J.P., Derancourt, J., Brillard, M., and Gauthier, F. 1990, Rat cystatin C: the complete amino acid sequence reveals a site for N-glycosylation. *Biol. Chem. Hoppe Seyler* 371 (Suppl), 161.
- [38] Saitoh, E. and Isemura, S. 1993, Molecular biology of human salivary cysteine protease inhibitors. *Crit. Rev. Oral. Biol. Med.* 4, 487.
- [39] Nishiura, T., Ishibashi, K., and Abe, K. 1991, Isolation of three forms of cystatin from submandibular saliva of isoproterenol-treated rats, its properties and kinetic data. *Biochem. Biophys. Acta* 1077, 346.
- [40] Popovic T, Brzin J, Ritonja A, and Turk V. Different forms of human cystatin C. *Biol Chem Hoppe-Seyler* 1990;371:575-80.
- [41] Tonnelle, C., Coll, A., Leclercq, M., Sire, J., and Manuel, Y. 1977, The different electrophoretic forms of post gamma-globulin their antigenic identity and their structural variability. *Biochem. Biophys. Acta* 490, 35.
- [42] Tonnelle, C., Coll, A., Fougereau, M., and Manuel, Y. 1979, Partial amino acid sequence of two forms of human post-gammaglobulin. *Biochem. Biophys. Res. Commun.* 86, 613.
- [43] Buttle, D.J., Abrahamson, M., Burnett, D., Mort, J.S., Barrett, A.J., Dando, P.M., and Hill, S.L. 1991, Human sputum cathepsin B degrades proteoglycan, is inhibited by alpha 2-macroglobulin and is modulated by neutrophil elastase cleavage of cathepsin B precursor and cystatin C. *Biochem. J.* 276, 325.
- [44] Cohen, D.H., Feiner, H., Jansson, O. and Frangione, B. 1983, Amyloid fibril in hereditary cerebral hemorrhage with amyloidosis (HCHWA) is related to the gastroentero-pancreatic neuroendocrine protein, gamma trace. *J. Exp. Med.* 158, 623.
- [45] Ghiso, J., Jansson, O., and Frangione, B. 1986, Amyloid fibrils in hereditary cerebral hemorrhage with amyloidosis of Icelandic type is a variant of gamma-trace basic protein (cystatin C). *Proc. Natl. Acad. Sci. USA* 83, 2974.
- [46] Asgeirsson, B., Haebel, S., Thorsteinsson, L., Helgason, E., Gudmundsson, K.O., Gudmundsson, G. and Roepstorff, P. 1998, Hereditary cystatin C amyloid angiopathy: monitoring the presence of the Leu-68->Gln cystatin C variant in cerebrospinal fluids and monocyte cultures by MS. *Biochem. J.* 329, 497.
- [47] Hall, A., Hakansson, K., Mason, R.W., Grubb, A., and Abrahamson, M. 1995, Structural basis for the biological specificity of cystatin C. Identification of leucine 9 in the N-terminal binding region as a selectivity-conferring residue in the inhibition of mammalian cysteine peptidases. *J. Biol. Chem.* 270, 5115.
- [48] Bode, W., Engh, R., Musil, D., Thiele, U., Huber, R., Karshikov, A., Brzin, J., Kos, J., and Turk, V. 1988, The 2.0 Å X-ray crystal structure of chicken egg white cystatin and its possible mode of interaction with cysteine proteases. *EMBO J.* 7, 2593.
- [49] Stubbs, M.T., Laber, B., Bode, W., Huber, R., Jerala, R., Lenar, I., B., and Turk, V. 1990, The refined 2.4 Å X-ray crystal structure of recombinant human stefin B in complex with the cysteine protease papain: a novel type of protease inhibitor interaction. *EMBO J.* 9, 1939.
- [50] Dieckmann, T., Mitschang, L., Hofmann, M., Kos, J., Turk, V., Auerswald, E.A., Jaenicke R., and Oschkinat, H. 1993, The structures of native phosphorylated chicken cystatin and of a recombinant unphosphorylated variant in solution. *J. Mol. Biol.* 234, 1048.
- [51] Martin, J.R., Jerala, R., Kroon-Zitko, L., Zerovnik, E., Turk, V., and Waltho, J.P. 1994, Structural characterisation of human stefin A in solution and implications for binding to cysteine proteases. *Eur. J. Biochem.* 225, 1181.
- [52] Martin, J.R., Craven, C.J., Jerala, R., Kroon-Zitko, L., Zerovnik, E., Turk, V., and Waltho, J.P. 1995, The three-dimensional solution structure of human stefin A. *J. Mol. Biol.* 246, 331.
- [53] Ekiel, I., Abrahamson, M., Fulton, D.B., Lindahl, P., Storer, A.C., Levadoux, W., Lafrance, M., Labelle, S., Pomerleau, Y., Groleau, D., LeSauter, L., and Gehring, K. 1997, NMR structural studies of human cystatin C dimers and monomers. *J. Mol. Biol.* 271, 266.
- [54] Buttle, D.J., Ritonja, A., Dando, P.M., Abrahamson, M., Shaw, E.N., Wikstrom, P., Turk, V., and Barrett, A.J. 1990, Interactions of papaya protease IV with inhibitors. *FEBS* 262, 58.
- [55] Abrahamson, M., Wikstrom, M., Potempa, J., Renvert, S., and Hall, A. 1997, Modification of cystatin C activity by bacterial proteases and neutrophil elastase in periodontitis. *Mol. Pathol.* 50, 291.
- [56] Pierre, P., and Mellman, I. 1998, Developmental regulation of invariant chain proteolysis controls MHC class II trafficking in mouse dendritic cells. *Cell* 93, 1135.
- [57] El-Sukkari, D., Wilson, N.S., Hakansson, K., Steptoe, R.J., Grubb, A., Shortman, K., and Villandangos, J.A. 2003, The protease inhibitor cystatin C is differentially expressed among dendritic cell populations, but does not control antigen presentation. *J. Immunol.* 171, 5003.

- [58] Lah, T.T., Babnik, J., Schiffmann, E., Turk, V., and Skalaric, U. 1993, Cysteine proteases and inhibitors in inflammation: their role in periodontal disease. *J. Periodontol.* 64, 485.
- [59] Henskens, Y.M.C., Veerman, E.C.I., Mantel, M.S., Van der Velden, U., and Nieuw Amerongen, A.V. 1994, Cystatins S and C in human whole saliva and in glandular salivas in periodontal health and disease. *J. Dent. Res.* 73, 1606.
- [60] Henskens, Y.M.C., van den Keijbus, P.A.M., Veerman, E.C.I., Van der Weijden, G.A., Timmerman, M.F., Snoek, C.M., Van der Velden, U., and Nieuw Amerongen, A.V. 1996, Protein composition of whole and parotid saliva in healthy and periodontitis subjects. Determination of cystatins, albumin, amylase and IgA. *J. Periodont. Res.* 31, 57.
- [61] Warfel, A.H., Cardozo, C., Yoo, O.H., and Zucker-Franklin, D. 1991, Cystatin C and cathepsin B production by alveolar macrophages from smokers and nonsmokers. *J. Leukocyte Biol.* 49, 41.
- [62] Chapman, H.A.Jr, Reilly, J.J.Jr, Yee, R., and Grubb, A. 1990, Identification of cystatin C, a cysteine protease inhibitor, as a major secretory product of human alveolar macrophages in vitro. *Am. Rev. Respir. Dis.* 141, 698
- [63] Keppler, D. 2006, Towards novel anti-cancer strategies based on cystatin function. *Cancer Lett.*, 235(2), 159.
- [64] Lah, T., and Kos, J. 1998, Cysteine proteases in cancer progression and their clinical relevance for prognosis. *Biol. Chem.* 379, 125.
- [65] Bollengier, F. 1987, Cystatin C, alias post-gamma-globulin: a marker for multiple sclerosis? *J. Clin. Chem. Clin. Biochem.* 25, 589.
- [66] Grubb, A. 2000, Cystatin C- properties and use as diagnostic marker. *Adv. Clin. Chem.* 35, 63.
- [67] Cimerman, N., Mesko Brguljan, P., Krasovec, M., Suskovic, S., and Kos, J. 2000, Serum cystatin C, a potent inhibitor of cysteine proteases, is elevated in asthmatic patients. *Clin. Chim. Acta* 300, 83.
- [68] Cimerman, N., Mesko Brguljan, P., Krasovec, M., Suskovic, S., and Kos, J. 2001, Serum concentration and circadian profiles of cathepsins B, H and L, and their inhibitors, stefins A and B, in asthma. *Clin. Chim. Acta* 310, 113.
- [69] Cimerman, N., Me_ko Brguljan, P., Krasovec, M., Suskovic, S., and Kos, J. 2001, Circadian and concentration profile of cathepsin S in sera from healthy subjects and asthmatic patients. *Pfl_gers. Arch.* 422[Suppl], R204.
- [70] Collé, A., Tavera, C., Prevot, D., Leung-Tack, J., Thomas, Y., Manuel, Y., Benveniste, J., and Leibowitch, J. 1992, Cystatin C levels in sera of patients with human immunodeficiency virus infection. A new avidin-biotin ELISA assay for its measurement. *J. Immunoassay* 13, 47.
- [71] Yamaza, T., Tsuji, Y., Goto, T., Kido, M.A., Nishijima, K., Moroi, R., Akamine, A., and Tanaka, T. 2001, Comparison in localization between cystatin C and cathepsin K in osteoclasts and other cells in mouse tibia epiphysis by immunolight and immunoelectron microscopy. *Bone* 29, 42.
- [72] Korant, B.D., Brzin, J., and Turk, V. 1985, Cystatin, a protein inhibitor of cysteine proteases alters viral protein cleavages in infected human cells. *Biochem. Biophys. Res. Commun.* 127, 1072.
- [73] Cimerman, N., Drobnic Kosorok, M., Korant, B.D., Turk, B., and Turk, V. 1996, Characterization of cystatin C from bovine parotid glands: cysteine protease inhibition and antiviral properties. *Biol. Chem. Hoppe-Seyler* 377, 19.
- [74] Bj_rck, L., Grubb, A., and Kjellen, L. 1990, Cystatin C, a human protease inhibitor, blocks replication of herpes simplex virus. *J. Virol.* 64, 941.
- [75] Collins, A.R., and Grubb, A. 1991, Inhibitory effects of recombinant human cystatin C on human coronaviruses. *Antimicrob. Agents Chemother.* 35, 2444.
- [76] Thomas, L., and Huber, A.R. 2006, Renal function – estimation of glomerular filtration rate. *Clin Chem Lab Med*, 44(11), 1295.1302.
- [77] Cockcroft, D.W., and Gault, M.H. 1976, Prediction of creatinine clearance from serum creatinine. *Nephron* 16, 31.
- [78] Stevens, L.A., and Levey, A.S. 2005, Measurement of kidney function. *Med. Clin. N. Am.* 89, 457.
- [79] O'Riordan, S.E., Webb, M.C., Stowe, H.J., Simpson, D.E., Kanarpa, M., Coakley, A.J., Newman, D.J., Saunders, J.A., and Lamb, E.J. 2003, Cystatin C improves the detection of mild renal dysfunction in older patients. *Ann. Clin. Biochem.* 40, 648.
- [80] National Kidney Foundation-K/DOQI. 2002, Clinical practice and guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am. J. Kidney Dis* 39(Suppl 1), S1-266.
- [81] Grubb, A., Nyman, U., Bjork, J., Lindstrom, V., Rippe, B., Sterner, G., and Christensson, 2005, Simple cystatin C-based prediction equations for glomerular filtration rate compared with Modification of Diet in Renal Disease prediction equation for adults and the Schwartz and the Counahan-Barratt prediction equations for children. *Clin. Chem.* 51(8), 1420-1431.
- [82] AKyhse-Andersen, J., Schmidt, C., Nordin, G., Andersson, B., Nilsson-Ehle, P., Lindström, V., and Grubb, A. 1994, Serum cystatin C, determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. *Clin. Chem.* 1994, 40, 1921.
- [83] Newman, D.J., Thakkar, H., Edwards, R.G., Wilkie, M., White, T., Grubb, A., and Price, C.P. 1995, Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. *Kidney International* 47, 312.
- [84] Finney, H., Newman, D.J., Gruber, W., Merle, P., and Price, C.P. 1997, Initial evaluation of cystatin C measurement by particle-enhanced immunonephelometry on the Behring nephelometer systems (BNA, BN II). *Clin. Chem.* 43, 1016.
- [85] Norlund, L., Grubb, A., Fex, G., Leksell, H., Nilsson, J.E., Schenck, H., and Hultberg, B. 1998, The increase of plasma homocysteine concentrations with age is partly due to the deterioration of renal function as determined by plasma cystatin C. *Clin. Chem. Lab. Med.* 36, 175.
- [86] Knight, E.L., Verhave, J.C., Spiegelman, D., Hillege, H.L., de Zeeuw, D., Curhan, G.C., and de Jong, P.E. 2004, Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. *Kidney Int.* 65, 1416.
- [87] Filler, G., B_kenkaamp, A., Hofmann, W., Le Bricon, T., Martinez-Br_, C., and Grubb, A. 2005, Cystatin C as a marker of GFR-history, indications, and future research. *Clin. Biochem.* 38, 1.
- [88] Cimerman, N., Mesko Brguljan, P., Krasovec, M., Suskovic, S., and Kos, J. 2000, Twenty-four hour variations of cystatin C and total cysteine protease inhibitory activity in sera from healthy subjects. *Clin. Chim. Acta* 291, 89.
- [89] Norlund, L., Grubb, A., Fex, G., Leksell, H., Nilsson, J.E., Schenck, H., and Hultberg, B. 1998, The increase of plasma homocysteine concentrations with age is partly due to the deterioration of renal function as determined by plasma cystatin C. *Clin. Chem. Lab. Med.* 36, 175.
- [90] Erlandsen, E.J., Randers, E., and Kristensen, J.H. 1998, Reference intervals for serum cystatin C and serum creatinine in adults. *Clin. Chem. Lab. Med.* 36, 393.
- [91] Finney, H., Newman, D.J., and Price, C.P. 2000, Adult reference ranges for serum cystatin C, creatinine and predicted creatinine clearance. *Ann. Clin. Biochem.* 37, 49.
- [92] Randers, E., Krue, S., Erlandsen, E.J., Danielsen, H., and Hansen L.G. 1999, Reference interval for serum cystatin C in children. *Clin. Chem.* 45, 1856.

- [93] B_kenkamp, A., Domanetzki, M., Zinck, R., Schumann, G., Byrd, D., and Brodehl, J. 1998, Cystatin C- a new marker of glomerular filtration rate in children independent of age and height. *Pediatrics* 101, 875.
- [94] Laterza, O.F., Price, C.P., and Scott, G. 2002, Cystatin C: an improved estimator of glomerular filtration rate? *Clin. Chem.* 48, 699.
- [95] Roos, J.F., Doust, J., Tett, S.E., and Kirkpatrick, C.M. 2007, Diagnostic accuracy of cystatin C compared to serum creatinine for estimation of renal dysfunction in adults and children – a meta-analysis. *Clin. Biochem.* 40(5-6), 383-91.
- [96] Fliser, D., and Ritz, E. 2001, Serum cystatin C concentration as a marker of renal dysfunction in the elderly. *Am. J. Kidney Dis.* 37, 79.
- [97] Randers, E., Erlandsen, E.J., Pedersen, O.L., Hasling, C., and Danielsen, H. 2000, Serum cystatin C as an endogenous parameter of the renal function in patients with normal to moderately impaired kidney function. *Clin. Nephrol.* 54, 203.
- [98] Meir, P., Froidevaux, C., Dayer, E., and Blanc, E. 2001, Cystatin C concentration and glomerular filtration rate. *Lancet* 357, 634.
- [99] Herget-Rosenthal, S., Trabold, S., Pietruck, F., Heemann, U., Philipp, T., and Kribben, A. 2000, Cystatin C: efficacy as screening test for reduced glomerular filtration rate. *Am. J. Nephrol.* 20, 97.
- [100] Risch, L., Drexel, H., and Huber, A.R. 2005, Differences in glomerular filtration estimates by two cystatin C-based equations. *Clin. Chem.* 51, 2211-2.
- [101] Grubb, A. 2007, Cystatin C as estimator of glomerular filtration rate: needs for its definitive implementation. *Clin. Chem. Lab. Med.* 45(Suppl.), S57.
- [102] Rule, A.D. 2007, Understanding estimated glomerular filtration rate: implications for identifying chronic kidney disease. *Curr. Opin. Nephrol. Hypertens.* 16(3), 242-9.
- [103] Stickle D., Cole, B., Hock, K., Hruska, K.A., and Scott, M.G. 1998, Correlation of plasma concentrations of cystatin C and creatinine to inulin clearance in a pediatric population. *Clin. Chem.* 44, 1334.
- [104] Montini, G., Cosmo, L., Amici, G., Mussap, M., and Zacchello, G. 2001, Plasma cystatin C values and inulin clearances in premature neonates. *Pediatr. Nephrol.* 16, 463.
- [105] Finney, H., Newman, D.J., Thakkar, H., Fell, J.M.E., and Price, C.P. 2000, Reference ranges for plasma cystatin C and creatinine measurements in premature infants, neonates, and older children. *Arch. Dis. Child* 82, 71.
- [106] Filler, G., Priem, F., Lepage, N., Sinha, P., Vollmer, I., Clark, H., Keely, E., Matzinger, M., Akbari, A., Althaus, H., and Jung, K. 2002, Beta-trace protein, cystatin C, beta(2)-microglobulin, and creatinine compared for detecting impaired glomerular filtration rates in children. *Clin. Chem.* 48, 729.
- [107] Filler, G., and Pham-Huy, A. 2002, Cystatin C should be measured in pediatric renal transplant patients! *Pediatr. Transplant.* 6, 357.
- [108] Fiscbach, M., Graff, V., Terzic, J., Berg_re V., Oudet, M., and Hamel, G. 2002, Impact of age on reference values for serum concentration of cystatin C in children. *Pediatr. Nephrol.* 17, 104.
- [109] Harmoinen, A., Ylinen, E., Ala-Houhala, M., Janas, M., Kaila, M., and Kouri, T. 2000, Reference intervals for cystatin C in pre- and full-term infants and children. *Pediatr. Nephrol.* 15, 105.
- [110] Pham-Huy, A., Leonard, M., Lepage, N., Halton, J., and Filler, G. 2003, Measuring glomerular filtration rate with cystatin C and beta-trace protein in children with spina bifida. *J. Urol.* 169, 2312.
- [111] Thomassen, S.A., Johannesen, I.L., Erlandsen, E.J., Abrahamson, J., and Randers, E. 2002, Serum cystatin C as a marker of the renal function in patients with spinal cord injury. *Spinal Cord* 40, 524.
- [112] Herrero-Morin, J.D., Malaga, S., Fernandez, N., Rey, C., Dieguez, M.A., Solis, G., Concha, A., and Medina, A. 2007, Cystatin C and beta2-microglobulin: markers of glomerular filtration in critically ill children. *Crit. Care* 11(3), R59.
- [113] Lamb, E.J., O'Riordan, S.E., and Delaney, M.P. 2003, Kidney function in older people: pathology, assessment and management. *Clin. Chim. Acta* 334, 25.
- [114] Okamoto, G., Sakamoto, T., Kimura, M., Ukishima, Y., Sonoda, A., Mori, N., Kato, Y., Maeda, T., and Kagawa, y. 2007, Serum cystatin C as a better marker of vancomycin clearance than serum creatinine in elderly patients. *Clin. Biochem.* 40(7), 485-90.
- [115] Tanaka, A., Suemaru, K., Otsuka, T., Ido, K., Nishimiya, T., Sakai, I., Hasegawa, H., Inoue, T., Murase, M., Yasukawa, M., and Araki, H. 2007, Estimation of initial dose setting of vancomycin therapy with use of cystatin C as a marker of renal function. *Ther. Drug Monit.* 29(2), 261-4.
- [116] Cataldi, L., Mussap, M., Bertelli, L., Ruzzantr, N., Fanos, V., and Plebani, M. 1999, Cystatin C in healthy women at term pregnancy and in their infant newborns: relationship between maternal and neonatal serum levels and reference values *Am. J. Perinatol.* 16, 287.
- [117] Nakanishi, T., Ozaki, Y., Blomgren, K., Tateyama, H., Sugiura-Ogasawara, M., and Suzumori, K. 2005, Role of cathepsins and cystatins in patients with recurrent miscarriage. *Mol. Hum. Reprod.* 11, 351.
- [118] Strevens, H., Wide-Swensson, D., and Grubb, A. 2001, Serum cystatin C is a better marker for preeclampsia than serum creatinine or serum urate. *Scand. J. Clin. Lab. Invest.* 61, 575.
- [119] Strevens, H., Wide-Swensson, D., Torffvit, O., and Grubb, A. 2002, Serum cystatin C for assessment of glomerular filtration rate in pregnant and non-pregnant women. Indications of altered filtration process in pregnancy. *Scand. J. Clin. Lab. Invest.* 62, 141.
- [120] Strevens, H., Wide-Swensson, D., Grubb, A., Hansen, A., Horn, T., Ingemarsson, I., Larsen, S., Nyengaard, J.R., Torffvit, O., Willner, J., and Olson, S. 2003, Serum cystatin C reflects glomerular endotheliosis in normal, hypertensive and pre-eclamptic pregnancies. *BJOG* 110, 825.
- [121] Shlipak, M.G., Sarnak, M.J., Katz, R., Fried, L.F., Seliger, S.L., Newman, A.B., Siscovick, D.S., and Stehman-Breen, C. 2005, Cystatin C and the risk of death and cardiovascular events among elderly persons. *N. Engl. J. Med.* 352, 2049.
- [122] Sarnak, M.J., Katz, R., Stehman-Breen, C.O., Fried, L.F., Jenny, N.S., Psaty, B.M., Newman, A.B., Siscovick, D.S., Shlipak, M.G., and Cardiovascular Health Study. 2005, Cystatin C concentration as a risk factor for heart failure in older adults. *Ann. Intern. Med.* 142, 497.
- [123] Lassus, J., Harjola, V.P., Sund, R., Siirila-Waris, K., Melin, J., Peuhkurinen, K., Pulkki, K., Nieminen, M.S. 2007, *Eur. Heart J.* 2, 8.
- [124] Koenig, W., Twardella, D., Brenner, H., and Rothenbacher, D. 2005, Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. *Clin. Chem.* 51, 321.
- [125] Artunc, H.F., Fischer, I.U., Risler, T., and Erley, C.M. 2005, Improved estimation of GFR by serum cystatin C in patients undergoing cardiac catheterization. *Int. J. Cardiol.* 102, 173.
- [126] P_ge, U., Gerhardt, T.M., Stoffel-Wagner, B., Palmedo, H., Klehr, H.U., Sauerbruch, T., and Woitas R.P. 2005, beta-Trace protein is an alternative marker for glomerular filtration rate in renal transplantation patients. *Clin. Chem.* 51, 1531.
- [127] Risch, L., Blumberg, A., and Huber, A.R. 2001, Assessment of renal function in renal transplant patients using cystatin C. A comparison to other renal function markers and estimates. *Ren. Fail.* 23, 439.
- [128] Zahran, A., Qureshi, M., and Shoker, A. 2007, Comparison between creatinine and cystatin C-based GFR equations in renal transplantation. *Nephrol. Dial. Transplant.* Apr 30.
- [129] LeBricon, T., Therivet, E., Froissart, M., Benlakehal, M., Bousquet, B., Legendre, C., and Erlich, D. 2000, *Clin. Chem.*, 46, 1206.
- [130] Leach, T.D., Kitiyakara, C., Price, C.P., Stevensen, J.M., and Newman, J.M. 2002, Prognostic significance of serum cystatin c concentrations in renal transplant recipients: 5-year follow-up. *Transplant. Proc.* 34, 1152.

- [131] White, C., Akbari, A., Hussain, N., Dinh, L., Filler, G., Lepage, N., and Knoll, G.A. 2007, Chronic kidney disease stage in renal transplantation – classification using cystatin C and creatinine-based equations. *Nephrol. Dial. Transplant*, Jun 7, in press.
- [132] LeBricon, T., Thervet, E., Benlakehal, M., Bousquet, B., Legendre, C., and Erlich, D. 1999, *Clin. Chem.* 45, 2243.
- [133] B_kenkamp, A., Domanetzki, M., Zinck, R., Schumann, G., Byrd, D., and Brodehl, J. 1999, *Clin. Chem.* 45, 1866.
- [134] Herget-Rosenthal, S., Trabold, S., Huesing, J., Heemann, U., Philipp, T., and Kribben, A. 2000, Cystatin C--an accurate marker of glomerular filtration rate after renal transplantation? *Transpl. Int.* 13, 285.
- [135] Woitas, R.P., Stoffel-Wagner, B., Flommersfeld, S., Poege, U., Schiedermaier, P., Klehr, H.U., Spengler, U., Bidlingmaier, F., and Sauerbruch, T. 2000, Correlation of Serum Concentrations of Cystatin C and Creatinine to Inulin Clearance in Liver Cirrhosis. *Clin. Chem.* 46, 712.
- [136] Takeuchi, M., Fukuda, Y., Nakano, I., Katano, Y., and Hayakawa, T. 2001, Elevation of serum cystatin C concentrations in patients with chronic liver disease. *Eur. J. Gastroenterol. Hepatol.* 13, 951.
- [137] Orlando, R., Mussap, M., Plebani, M., Piccoli, P., De Martin, S., Floreani, M., Padrini, R., and Palatini, P. 2002, Diagnostic value of plasma cystatin C as a glomerular filtration marker in decompensated liver cirrhosis. *Clin. Chem.* 48, 850.
- [138] Hermida, J., Romero, R., and Tutor, J.C. 2002, Relationship between serum cystatin C and creatinine in kidney and liver transplant patients. *Clin. Chim. Acta* 316, 165.
- [139] Gerbes, A.L., Gulberg, V., Bilzer, M., and Vogeser, M. 2002, Evaluation of serum cystatin C concentration as a marker of renal function in patients with cirrhosis of the liver. *Gut* 50, 106.
- [140] Leung, N. 2002, A tale of two markers. *Liver Transplant.* 8, 600.
- [141] Samyn, M., Cheeseman, P., Bevis, L., Taylor, R., Samaro, B., Buxton-Thomas, M., Heaton, N., Rela, M., Mieli-Vergani, G., and Dhawan, A. 2005, Cystatin C, an easy and reliable marker for assessment of renal dysfunction in children with liver disease and after liver transplantation. *Liver Transpl.* 11, 344.
- [142] Harmoinen, A.P., Kouri, T.T., Wirta, O.R., Lehtimäki, T.J., Rantalaiho, V., Turjanmaa, V.M., and Pasternack, A.I. 1999, Evaluation of plasma cystatin C as a marker for glomerular filtration rate in patients with type 2 diabetes. *Clin. Nephrol.* 52, 363.
- [143] Perkins, B.A., Nelson, R.g., Ostrander, B.E., Blouch, K.L., Krolewski, A.S., Myers, B.D., and Warram, J.H. 2005, Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. *J Am Soc Nephrol.* 16, 1404.
- [144] Mangge, H., Liebmann, P., Tanil, H., Herrmann, J., Wagner, C., Gallistl, S., Schauenstein, K., and Erwa, W. 2000, Cystatin C, an early indicator for incipient renal disease in rheumatoid arthritis. *Clin. Chim. Acta* 300, 195.
- [145] Pucci, L., Triscornia, S., Lucchesi, D., Fotino, C., Pellegrini, G., Pardini, E., Micolli, R., Del Prato, S., and Penno, G. 2007, Cystatin C and estimates of renal function: searching for a better measure of kidney function in diabetic patients. *Clin. Chem.* 53(3), 480-8.
- [146] Yang, Y.S., Peng, C.H., Lin, C.K., Wang, C.P., and Huang, C.N. 2007, Use of serum cystatin C to detect early decline of glomerular filtration rate in type 2 diabetes. *Intern. Med.* 46(12), 801-6.
- [147] Macisaac, R.J., Tsalamandris, C., Thomas, M.C., Premaratne, E., Panagiotopoulos, s., Smith, T.J., Poon, A., Jenkins, M.A., Ratnaike, S.I., Power, D.A., and Jerums, G. 2007, The accuracy of cystatin C and commonly used creatinine-based methods for detecting moderate and mild chronic kidney disease in diabetes. *Diabet. Med.* 24(4), 443-8.
- [148] Villa, P., Jimenez, M., Soriano, M.C., Menzhanes, J., and Casanovas, P. 2005, Serum cystatin C concentration as a marker of acute renal dysfunction in critically ill patients. *Critical Care* 9, R139.
- [149] Johnston, N., Jernberg, T., Lindhal, B., Lindb_ck, J., Stritsberg, M., Larsson, A., Venge, P., and Wallentin, L. 2004, Biochemical indicators of cardiac and renal function in a healthy elderly population. *Clin. Biochem.* 37, 210.
- [150] Risch, L., Herklotz, R., Blumberg, A., Huber, A.R. 2001, Effects of glucocorticoid immunosuppression on serum cystatin C concentrations in renal transplant patients. *Clin. Chem.* 47, 2055.
- [151] Risch, L., and Huber, A.R. 2002, Glucocorticoids and increased serum cystatin C concentrations. *Clin. Chim. Acta* 320, 133.
- [152] Risch, L., Saely, C., Reist, U., Reist, K., Hefli, M., and Huber, A.R. 2005, Course of glomerular filtration rate markers in patients receiving high-dose glucocorticoids following subarachnoidal hemorrhage. *Clin. Chim. Acta*, 360, 205.
- [153] Bjarnadottir, M., Grubb, A., and Olafsson, I. 1995, Promoter-mediated, dexamethasone-induced increase in cystatin C production by HeLa cells. *Scand. J. Clin. Lab. Invest.* 55, 617.
- [154] Jayagopal, V., Keevil, B.G., Atkin, S.L., Jennings, P.E., and Kilpatrick, E.S. 2003, Paradoxical changes in cystatin C and serum creatinine in patients with hypo- and hyperthyroidism. *Clin. Chem.* 49, 680.
- [155] Fricker, M., Wiesli, P., Brandle, M., Schwegler, B., and Schmid, C. 2003, Impact of thyroid dysfunction on serum cystatin C. *Kidney Int.* 63, 1944.
- [156] Wiesli, P., Schwegler, B., Spinass, G.A., and Schmid, C. 2003, Serum cystatin C is sensitive to small changes in thyroid function. *Clin. Chim. Acta* 338, 87.
- [157] den Hollander, J.G., Wulkan, R.W., Mantel, M.J., and Berghout, A. 2003, Is cystatin C a marker of glomerular filtration rate in thyroid dysfunction? *Clin. Chem.* 49, 1558.
- [158] Mannetti, L., Pardini, E., Genovesi, M., Campomori, A., Grasso, L., Morselli, L.L., Lupi, I., Pellegrini, G., Bartalena, L., Bogazzi, F., and Martino, E. 2005, Thyroid function differently affects serum cystatin C and creatinine concentrations. *J. Endocrinol. Invest.* 28, 346.
- [159] Grubb, A., Simonsen, O., Sturfelt, G., Truedsson, L. and ThySELL, H. 1985, Serum concentration of cystatin C, factor D and beta 2-microglobulin as a measure of glomerular filtration rate. *Acta Med. Scand.* 218, 499.
- [160] Stabuc, B., Vrhovec, L., Stabuc-Silih, M., Cizej, T.E. 2000, Improved prediction of decreased creatinine clearance by serum cystatin C: use in cancer patients before and during chemotherapy. *Clin. Chem.* 46, 193.
- [161] Finney, H., Williams, A.H., and Price, C.P. 2001, Serum cystatin C in patients with myeloma. *Clin. Chim. Acta* 309, 1.
- [162] Kos, J., Stabuc, B., Schweiger, A., Krasovec, M., Cimerman, N., Kopitar-Jerala, N., and Vrhovec, I. 1997, Cathepsins B, H, and L and their inhibitors stefin A and cystatin C in sera of melanoma patients. *Clin. Cancer. Res.* 3, 1815.
- [163] Kos, J., Stabuc, B., Cimerman, N., and Brünner, N. 1998, Serum cystatin C, a new marker of glomerular filtration rate, is increased during malignant progression. *Clin. Chem.* 44, 2556.
- [164] Kos, J., Krasovec, M., Cimerman, N., Nielsen, H.J., Christensen, and Br_nner, N. 2000, Cysteine protease inhibitors stefin A, stefin B, and cystatin C